participants received canagliflozin 300 mg once daily
on days 1 to 7; during period 2, participants received
HCTZ 25 mg once daily for 28 days (days 1–28),
followed by the combination of canagliflozin 300 mg
þ HCTZ 25 mg once daily for 7 days (days 29–35).
Participants were domiciled at the study center during
days 3 to 8 of period 1, and days 3 to 1 and days
26 to 36 of period 2. Participants received standardized
meals while at the study center; the meals
contained sodium not exceeding 2.5 g/d and calcium